Close

Have A Question?


Connect with Camargo today.

Contact Us
Blog & Resources Camargo Blog Product Selection and Planning

The Camargo Blog

Get insight and information from our team of experts to improve your pharmaceutical development and commercialization strategy.


November 8th, 2018

Market Assessment:

March 21st, 2018

Product Ideation: Who Wants to Develop a Successful Product?

September 20th, 2017

The Race to Get a Cannabidiol Product Approved: Why Is It Taking So Long?

June 21st, 2017

PREA Requirements for Biosimilar and Interchangeable Biological Products

June 7th, 2017

Brexit and EMA: The Changes Have Begun

April 5th, 2017

Shortening the Review Clock: the Latest on Priority Review Vouchers

August 24th, 2016

Improving Drug Development ROI in 2017

July 13th, 2016

The Prodrug Benefit of Utilizing the 505(b)(2) Pathway

April 6th, 2016

Product Ideation: Identifying Your Optimal Drug Development Candidate

September 13th, 2015

Enforcement Activities: FDA Removes Unapproved Prescription Ear Drops

July 20th, 2015

Final Rule—Drug Shortage Regulation: Incentive for Development of “Unapproved” Drugs?

June 14th, 2015

Active Ingredients vs. Active Moieties—Perplexity of Understanding the Relationship or Distinction

June 2nd, 2015

Pediatrics—What are the appropriate age ranges?

March 24th, 2015

Opportunities in Orphan Drug Development for Investors, Pharma and CROs

March 11th, 2015

REMS/ETASU and Safe Use in Bioequivalence Trials

December 10th, 2014

Therapeutic Equivalence Ratings Under 505(b)(2)

November 24th, 2014

Orphan Drug Exclusivity for a Previously Approved Drug: a 505(b)(2) Conundrum

September 22nd, 2014

Paper Submissions: Going, Going… Away

July 22nd, 2014

MannKind Breathes Easier—Inhaled Insulin Finally Approved

June 30th, 2014

Importing Pre-Launch Products with a Bit of PLAIR

April 8th, 2014

The Road to Commercial Success—The Target Product Profile

January 19th, 2014

2013 505(b)(2) NDA Approvals

July 30th, 2013

ANDA but No NDA—What to Rely On?

July 26th, 2013

PREA—Pediatric Plan Timing Changed by PDUFA V

Page 1 of 5


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101, Mill No. 1
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights